Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Grosskreutz, Julian
NCT05633459: A Study Evaluating the Safety and Tolerability of QRL-201 in ALS	Recruiting	1	64	Europe, Canada	Multiple ascending doses of QRL-201, Multiple ascending doses of Placebo, QRL-201, Placebo	QurAlis Corporation	Amyotrophic Lateral Sclerosis	08/26	08/26
NfL-ALS, NCT06201650: Neurofilament Light Chain in Amyotrophic Lateral Sclerosis	Recruiting	N/A	3000	Europe	Neurofilament light chain	Charite University, Berlin, Germany, Boris Canessa ALS Stiftung	Amyotrophic Lateral Sclerosis, Motor Neuron Disease	12/24	12/24
Matte, Genevieve
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)	Terminated	3	489	Europe, Canada, US, RoW	Reldesemtiv, Placebo	Cytokinetics	Amyotrophic Lateral Sclerosis	07/23	07/23
NCT05633459: A Study Evaluating the Safety and Tolerability of QRL-201 in ALS	Recruiting	1	64	Europe, Canada	Multiple ascending doses of QRL-201, Multiple ascending doses of Placebo, QRL-201, Placebo	QurAlis Corporation	Amyotrophic Lateral Sclerosis	08/26	08/26
iMMersioN, NCT05988073: A Prospective Longitudinal Study in Adults with Multifocal Motor Neuropathy	Active, not recruiting	N/A	413	Europe, Canada, Japan, US, RoW		argenx	Multifocal Motor Neuropathy	11/25	11/25
PROBIO_HA114, NCT06051123: Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients	Recruiting	N/A	150	Canada	Probiotic, Placebo	Centre hospitalier de l'Université de Montréal (CHUM), Lallemand Health Solutions	ALSFTD	02/27	02/27